Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 13/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14773762 | 0.94 | CACNA1I (0.39) | CACNA1IKCNH2NPC1RAB9ACA12 | |
| SCHEMBL4269196 | 0.91 | CACNA1I (0.46) | CACNA1IKCNH2NPC1RAB9ACA12 | |
| SCHEMBL4270993 | 0.90 | CACNA1I (0.45) | CACNA1IKCNH2NPC1RAB9ACA12 | |
| SCHEMBL4278887 | 0.89 | CACNA1I (0.46) | CACNA1IKCNH2NPC1RAB9ACA12 | |
| SCHEMBL4275588 | 0.88 | CACNA1I (0.45) | CACNA1IKCNH2NPC1RAB9ACA12 | |
| SCHEMBL19112805 | 0.86 | CACNA1I (0.48) | CACNA1IKCNH2NPC1RAB9ACACNA1H | |
| SCHEMBL14773819 | 0.85 | CACNA1I (0.40) | CACNA1IKCNH2NPC1RAB9ACA12 | |
| SCHEMBL19112992 | 0.85 | CACNA1I (0.47) | CACNA1IKCNH2NPC1RAB9ACACNA1H | |
| SCHEMBL14773761 | 0.84 | CACNA1I (0.40) | CACNA1IKCNH2NPC1RAB9ACA12 | |
| SCHEMBL19113214 | 0.83 | KCNH2 (0.44) | CACNA1IKCNH2NPC1RAB9ACACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189839-B1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | PRAXIS PREC MEDICINES INC (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-2300007-B1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TARO PHARMACEUTICALS INC (CA) | 2018-04-18 | — | — | EP | disclosed |
| EP-3189839-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Taro Pharmaceuticals Inc. (CA) | 2017-07-12 | — | — | EP | disclosed |
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS, LTD. (CA) | 2016-06-23 | — | — | US | disclosed |
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS, LTD. (CA) | 2016-06-23 | — | — | US | disclosed |
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS, LTD. (CA) | 2016-06-23 | — | — | US | disclosed |
| US-9096522-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-9096522-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-9096522-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-20140011996-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2014-01-09 | — | — | US | disclosed |
| US-8569344-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2013-10-29 | — | — | US | disclosed |
| US-8569344-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2013-10-29 | — | — | US | disclosed |
| US-20130065926-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2013-03-14 | — | — | US | disclosed |
| US-20130065926-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2013-03-14 | — | — | US | disclosed |
| US-8377968-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2013-02-19 | — | — | US | disclosed |
| US-8377968-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2013-02-19 | — | — | US | disclosed |
| US-8377968-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2013-02-19 | — | — | US | disclosed |
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065926-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | CACNA1I 4/4885KCNH2 60/4885NPC1 1266/4885 |
| US-20140011996-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | CACNA1I 4/4885KCNH2 60/4885NPC1 1266/4885 |
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | CACNA1I 4/4885KCNH2 60/4885NPC1 1266/4885 |
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | CACNA1I 4/4885KCNH2 60/4885NPC1 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.